Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells

Docetaxel has been the standard first-line therapy in metastatic castration resistant prostate cancer. The survival benefit is, however, limited by either primary or acquired resistance. In this study, Du145 prostate cancer cells were converted to docetaxel-resistant cells Du145-R and Du145-RB by in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuanjun, Miao, Yali, Peng, Zhuochun, Sandgren, Johanna, De Ståhl, Teresita Díaz, Huss, Mikael, Lennartsson, Lena, Liu, Yanling, Nistér, Monica, Nilsson, Sten, Li, Chunde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078122/
https://www.ncbi.nlm.nih.gov/pubmed/27822437
http://dx.doi.org/10.1186/s40064-016-3543-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078122/
https://www.ncbi.nlm.nih.gov/pubmed/27822437
http://dx.doi.org/10.1186/s40064-016-3543-0

Ejemplares similares